于羅欣】到【人力資源】7591477.png)
Luoxin Pharmaceutical，Source of Health
于羅欣】到【人力資源】6837549.png)
Luoxin Pharmaceutical，Source of Health
于羅欣】到【人力資源】2051292.png)
Luoxin Pharmaceutical，Source of Health
于羅欣】到【人力資源】4595412.png)
Luoxin Pharmaceutical，Source of Health
于羅欣】到【人力資源】4842313.png)
Luoxin Pharmaceutical，Source of Health
責(zé)任7779809.png)
Luoxin Pharmaceutical，Source of Health
I．The First Series: Anti-infective APIs & Intermediates | ||||||||
Cephalosporis | ||||||||
NO. | Compendial Name | Quality Specification | CGMP Status | International Registration & Certification
| CAS NO.
| |||
1 | Cefoperazone Sodium | USP,EP,BP, CP | √ | DMF available, and registered in India, Egypt and Vietnam | 62893-20-3 | |||
2 | Cefuroxime Sodium | USP,EP, BP, CP, IP | √ | DMF available, and registered in India | 56238-63-2 | |||
3 | Ceftizoxime Sodium | USP, JP,CP | √ | DMF available and registered in India, Vietnam, Egypt. | 68401-82-1 | |||
Intermediate | Ceftizoxime acid | 86299-50-5 | ||||||
4 | Cefepime Hydrochloride | USP,IP, CP | √ | DMF available, and registered in India, Egypt. | 107648-80-6 | |||
5 | Ceftazidime | USP,EP, BP, CP | √ | DMF available, and registered in India | 78439-06-2 | |||
6 | Cefotiam Hydrochloride | USP, JP | √ | DMF available, and registered in Japan, Korea. | 66309-69-1 | |||
Intermediate | Cefotiam Hydrochloride crude | |||||||
7 | Ceftezole Sodium | CP | √ | DMF available, and registered in Korea. | 41136-22-5 | |||
8 | Cefazedone Sodium | KP | √ | DMF available, and registered in Korea, Vietnam | 33564-30-6 | |||
Intermediate | Cefazedone acid | 56187-47-4 | ||||||
9 | Cefamandole Nafate | USP,EP,BP, CP | √ | DMF available, and registered in India. | 42540-40-9 | |||
NO. | Compendial Name | Quality Specification | CGMP Status |
International Registration & Certification | CAS NO. | |||
10 | Cefathiamidine | CP | √ | 33075-00-2 | ||||
Intermediate | Cefathiamidine Crude | |||||||
11 | Ceftriaxone Sodium | USP,EP ,JP,BP,CP | √ | DMF available, and registered in India. | 104376-79-6 | |||
12 | Cefotaxime Sodium | USP,EP BP, CP | √ | DMF available, and registered in India. | 64485-93-4 | |||
13 | Cefoxitin Sodium | USP,EP,BP, CP | √ | 33564-30-6 | ||||
14 | Cefonicid Sodium | USP , CP | √ | 61270-78-8 | ||||
15 | Cefodizime Sodium | JP | √ | 86329-79-5 | ||||
16 | Cefpirome Sulfate | JP | √ | 98753-19-6 | ||||
17 | Cefmenoxime Hydrochloride | USP | 75738-58-8 | |||||
18 | Cefminox Sodium | CP | √ | 75498-96-3 | ||||
19 | Cefpiramide | USP,JP | √ | 70797-11-4 | ||||
20 | Cefpiramide Sodium | JP | 74849-93-7 | |||||
21 | Cephalothin Sodium | CP | √ | 58-71-9 | ||||
22 | Cefprozil | USP | 121123-17-9 | |||||
23 | Cefetamet Pivoxil | JP | 111696-23-2 | |||||
24 | Cefteram Pivoxil | JP | 82547-58-8 | |||||
NO. | Compendial Name | Quality Specification | CGMP Status
| International Registration & Certification | CAS NO.
| |||
25 | Cefixime | USP,EP ,BP,CP, IP | √ | 79350-37-1 | ||||
26 | Cefdinir | USP | 91832-40-5 | |||||
27 | Cefcapene Pivoxil Hydrochloride | JP | 147816-24-8 | |||||
28 | Cefditoren Pivoxil | JP | 117467-28-4 | |||||
29 | Ceftibuten | JP | 97519-39-6 | |||||
30 | Cefmetazole Sodium | CP | 56796-39-5 | |||||
Quinolone APIs | ||||||||
NO.
| Compendial Name | Quality Specification | CGMP Status | International Registration & Certification | CAS NO.
| |||
31 | Moxifloxacin Hydrochloride | JP | 186826-86-8 | |||||
Intermediate | 1-Cyclopropyl-6,7-difluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid ethyl ester | 139693-52-0 | ||||||
32 | Sitafloxacin | IH | 127254-12-0 | |||||
33 | Balofloxacin | CP | √ | 127294-70-6 | ||||
34 | Prulifloxacin | CP | √ | 123447-62-1 | ||||
35 | Enoxacin Gluconate | CP | √ | 471-53-4 | ||||
Other Anti-infective APIs & Intermediates | ||||||||
NO.
| Compendial Name | Quality Specification | CGMP Status | International Registration & Certification | CAS NO.
| |||
36 | Sulbactam Sodium | USP,EP , BP,CP | √ | DMF available, and registered in India, Korea. | 69388-84-7 | |||
37 | Tazobactam | CP | 89786-04-9 | |||||
38 | Biapenem | JP | √ | 120410-24-4 | ||||
39 | Meropenem | CP | 96036-03-2 | |||||
40 | Aztreonam (or with L-arginine) | USP,CP ,IP | √ | DMF available，and to be registered in Vietnam | ---- | |||
Intermediate | δ- Aztreonam | 78110-38-0 | ||||||
41 | Nifutatel | CP | √ | 4936-47-4 | ||||
Ⅱ. The Second Series: Antiviral APIs & Intermediates | ||||||||
NO. | Compendial Name
| Quality Specification | CGMP Status | International Registration & Certification | CAS NO.
| |||
1 | Ganciclovir | USP,EP, BP,CP | √ | 82410-32-0 | ||||
2 | Lamivudine | USP,EP, BP | √ | DMF available, and Registered in India. | 134678-17-4 | |||
3 | Tenofovir Disoproxil Fumarate | IP |
202138-50-9 | |||||
4 | Entecavir | EP | 142217-69-4 | |||||
5 | Telbivudine | EP | 3424-98-4 | |||||
Ⅲ. The Third Series: Respiratory System APIs & Intermediates | ||||||||
NO. | Compendial Name | Quality Specification | CGMP Status
|
International Registration & Certification | CAS NO.
| |||
1 | Ambroxol Hydrochloride | EP, BP,CP | √ | DMF available, registered in Japan | 23828-92-4 | |||
2 | Ciclesonide | EP | 126544-47-6 | |||||
Ⅳ. The Fourth Series: Digestive System APIs & Intermediates | ||||||||
NO. | Compendial Name | Quality Specification |
CGMP Status
| International Registration & Certification | CAS NO.
| |||
1 | Omeprazole Enteric-coated Pellets | USP | √ | 73590-58-6 | ||||
2 | Lansoprazole | USP, EP, BP | √ | 103577-45-3 | ||||
3 | Pantoprazole Magnesium | IP | 1022083-88-0 | |||||
4 | Esomeprazole sodium | IP | 161796-78-7 | |||||
Intermediate | Omeprazole sulfide | 73590-85-9 | ||||||
5 | Esomeprazole Magnesium | USP , BP | 161973-10-0 | |||||
Intermediate | Esomeprazole magnesium trihydrate | 217087-09-7 | ||||||
6 | Rabeprazole Sodium | EP | 117976-90-6 | |||||
Intermediate | 117977-21-6 | |||||||
Intermediate | Rabeprazole | 117976-89-3 | ||||||
7 | (R)-Lansoprazole | IP | 138530-94-6 | |||||
8 | Racecadotril | CP | 81110-73-8 | |||||
9 | Tropisetron Hydrochloride | CP | 105826-92-4 | |||||
10 | Tiopronin | CP | √ | 1953-02-2 | ||||
Ⅴ. The Fifth Series: Nervous System APIs & Intermediates | ||||||||
NO. | Compendial Name | Quality Specification |
CGMP Status
| International Registration & Certification
| CAS NO.
| |||
1 | Edaravone | JP | 89-25-8 | |||||
2 | Menantine Hydrochloride | KP | 41100-52-1 | |||||
3 | Donepezil Hydrochloride | USP | 110119-84-1 | |||||
4 | Oxiracetam | JP | 62613-82-5 | |||||
Ⅵ. The Sixth Series: Endocrine System APIs & Intermediates | ||||||||
NO. | Compendial Name | Quality Specification | CGMP Status |
International Registration & Certification
| CAS NO.
| |||
1 | Vildagliptin | EP | 274901-16-5 | |||||
2 | Nateglinide | USP, EP | 105816-04-4 | |||||
Intermediate 1 |
Nateglinide methyl ester | 105746-47-2 | ||||||
Intermediate 2 | 4-(4-Aminophenoxy)-N-methylpicolinamide | 105816-04-4 | ||||||
3 | Levothyroxine Sodium | USP,EP,BP | √ | 867-81-2 | ||||
Ⅶ. The Seventh Series: Cardiovascular System APIs & Intermediates | ||||||||
NO. | Compendial Name | Quality Specification | CGMP Status
|
International Registration & Certification | CAS NO.
| |||
1 | Simvastatin | USP、CP | 79902-63-9 | |||||
2 | Carbazochrome Sodium Sulfonate | JP | √ | 51460-26-5 | ||||
3 | Fasudil Hydrochloride | CP | √ | 103745-39-7 | ||||
4 | Tirofiban Hydrochloride | USP | 150915-40-5 | |||||
5 | Clopidogrel Hydrogen Sulfate | EP | 120202-66-6 | |||||
6 | Ezetimibe | USP | 163222-33-1 | |||||
7 | Creatine Phosphate Sodium | EP | 922-32-7 | |||||
8 | Argatroban | JP | 141396-28-3 | |||||
9 | Pitavastatin Calcium | JP | 147526-32-7 | |||||
10 | Olmesartan MedoxomiI | JP | 144689-63-4 | |||||
11 | Dabigatran Etexilate Mesylate | EP | 872728-81-9 | |||||
12 | Ticagrelor | USP | 274693-27-5 | |||||
Intermediate |
| 376608-74-1 | ||||||
13 | Sotalol Hydrochloride | USP,EP,BP, CP | √ | 959-24-0 | ||||
14 | Tadalafil | USP | 171596-29-5 | |||||
Intermediate 1 |
| 14907-27-8 | ||||||
Intermediate 2 |
| 171752-68-4 | ||||||
Intermediate 3 |
| 171489-59-1 | ||||||
15 | Sildenafil Citrate | USP | 171599-83-0 | |||||
Ⅷ. The Eighth Series: Antipyretic, Analgesics and Anti-inflammatory APIs & Intermediates | ||||||||
NO. | Compendial Name | Quality Specification | CGMP Status | International Registration & Certification | CAS NO.
| |||
1 | Ketorolac Tromethamine | USP | 74103-07-4 | |||||
2 | Loxoprofen Sodium | JP | 80382-23-6 | |||||
3 | Parecoxib Sodium | EP | 198470-85-8 | |||||
4 | Cisatracurium Besilate | EP | 96946-42-8 | |||||
5 | Nalmefene Hydrochloride | USP | 58895-64-0 | |||||
6 | Diflunisal | USP, EP | 22494-42-2 | |||||
7 | Guacetisal | CP | 55482-89-8 | |||||
8 | Olopatadine Hydrocholoride | JP | 113806-05-6 | |||||
9 | Sodium New Houttuyfonate | IH | √ | 1847-58-1 | ||||
Ⅸ. The Ninth Series: Oncology APIs & Intermediates | ||||||||
NO. | Compendial Name | Quality Specification | CGMP Status | International Registration & Certification | CAS NO.
| |||
1 | Gemcitabine Hydrochloride | USP,EP,BP | √ | 122111-03-9 | ||||
2 | Irinotecan Hydrochloride | USP | √ | 136572-09-3 | ||||
3 | Oxaliplatin | USP,EP, BP | √ | 61825-94-3 | ||||
4 | Erlotinib Hydrochloride | JP | 183319-69-9 | |||||
Intermediate 1 |
| 179688-29-0 | ||||||
Intermediate 2 |
| 183322-18-1 | ||||||
Intermediate 3 | Erlotinib Base | 183321-74-6 | ||||||
5 | Sorafenib Tosylate | EP | 475207-59-1 | |||||
Intermediate 1 | 4-(4-Aminophenoxy)-N-methylpicolinamide | 284462-37-9 | ||||||
Intermediate 2 | Sorafenib | 284461-73-0 | ||||||
6 | Gefitinib | EP | 184475-35-2 | |||||
7 | Dasatinib | USP | 863127-77-9 | |||||
8 | Lapatinib Ditosylate | EP | 388082-78-8 | |||||
9 | Capecitabine | USP | 154361-50-9 | |||||
10 | Fosaprepitant Dimeglumine | USP | 265121-04-8 | |||||
11 | Bortezomib | JP, USP | 179324-69-7 | |||||
12 | Lenalidomide | USP | 191732-72-6 | |||||
Intermediate | 3-(4-Nitro-1-oxo-1,3-dihydroisoindol-2-yl)piperidine-2,6-dione | 827026-45-9 | ||||||
X. The Tenth Series:Anti-allergicAPIs & Intermediates | ||||||||
1 | Loratadine | USP,EP,BP, CP | √ | 79794-75-5 | ||||
_500502339_放飛鴿子（企業(yè)商用）_gaitubao_326x1443708017.jpg)